At a glance
ClinicalIndex Comparison RecordN/ACompleted· 394 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence (RWE) of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Poland (HCV RWE PMOS)
In Brief
An observational study for Chronic Hepatitis C. Completed, enrolled 394 participants.
Detailed Summary
This study seeks to provide evidence of the effectiveness and obtain patient reported outcomes (PRO) and work productivity data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), +/- dasabuvir (DSV), +/- ribavirin (RBV) in chronic hepatitis C virus infected patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
CollaboratorsIST GmbH, Germany
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedDec 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedDec 29, 2015
Enrollment StartNov 26, 2015
Primary CompletionMar 29, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.5 years ago